Search Results (244)

Diatom nanotechnology offers significant potential for the development of innovative diatom-based nanocarriers for drug delivery and bioimaging, with promising implications for the treatment and diagnosis of diverse diseases. However, clinical translation of these nanocarriers remains limited due to an incomplete understanding of their in vivo fate. Current studies on the biodistribution, intracellular behavior, biodegradation, and clearance of diatom-based nanocarriers are inadequate and often lack systematic evaluation, leaving critical knowledge gaps. A comprehensive understanding of how these nanocarriers traverse biological barriers, interact with cellular components, and are ultimately eliminated from the body is essential for their rational design and safe clinical implementation. This perspective critically examines the in vivo fate of diatom-based nanocarriers, highlighting recent advances while identifying key challenges and unresolved questions. By integrating insights into their biodistribution, intracellular interactions, toxicological profile, biodegradation, and clearance mechanisms, this article provides a framework to guide the development of more effective and clinically relevant diatom-based nanoplatforms. Furthermore, it outlines future research directions and design strategies for next-generation nanoformulations, aiming to accelerate their translation from bench to the bedside. Full article

Empowered by nanotechnology, messenger RNA (mRNA) therapeutics have shown a rapid evolution post COVID-19 from a conceptual platform to a clinically validated modality, and they diversified into oncology, cardiovascular diseases, and rare disorders. As a template for in situ protein production, it offers several advantages over traditional proteins and DNA drugs. The intrinsic stability of mRNA and its sensitivity to innate immune sensing hinder its capacity for immediate cellular entry, necessitating its need for a delivery system to obtain optimal therapeutic potential. This review explores the innovations in nanocarrier engineering, design principles for lipid nanoparticles-mRNA (LNPs) platforms, and their clinical translation across the prominent indications. It also addresses their safety, immunogenicity, and scalability while addressing the key limitations and manufacturing scalability through comparative platform analysis. Although LNPs usually dominate their delivery through encapsulation and manufacturability, their limitations, like repeat dose reactogenicity and liver tropism, require next-generation designs like SORT lipids, stimuli-responsive hybrids for extrahepatic targeting. In oncology, LNP-mRNA drives the neoantigen vaccines, and rare diseases leverage the transient enzyme replacement. While the safety profiles highlight the innate immune tuning through nucleoside mods and lipid biodegradability, chronic administration risks are still persistent. While there are novel scalability options like microfluidic mixing to support the production gaps in organ selectivity and durability, their adoption is hindered. We outline the future directions to perceive mRNA’s full potential as a broader therapeutic class. Full article

This narrative review examines topical anti-inflammatory therapies in veterinary medicine through the lens of the One Health framework, integrating pharmacology, dermatology, ecotoxicology, food safety, and regulatory science. It discusses the interconnected roles of veterinarians, pharmacists, environmental scientists, public health authorities, and regulatory bodies in addressing antimicrobial resistance, environmental contamination, zoonotic transmission, and drug residues in food-producing animals. By emphasising cross-sector collaboration, the review highlights how coordinated strategies can enhance animal welfare, safeguard human health, and reduce ecological burden. The article analyses inflammatory conditions in companion and farm animals and compares systemic versus topical anti-inflammatory approaches. Particular attention is given to corticosteroids, NSAIDs, immunomodulators, pro-resolving lipid mediators, and plant-derived bioactives, alongside advances in vehicles such as lipid nanocarriers and biodegradable film-forming systems designed to minimise systemic absorption and environmental dispersion. Regulatory considerations, residue control, pharmacovigilance gaps, and sustainability-oriented formulation strategies are critically addressed. Topical anti-inflammatory therapies, when rationally designed and monitored under One Health principles, represent a strategic opportunity to improve therapeutic precision while limiting systemic toxicity and ecological impact. Future directions should prioritise translational research, eco-compatible formulation design, and harmonised regulatory frameworks. Full article

In this study, Paliperidone Palmitate (PP), a second-generation antipsychotic, commonly used for the treatment of schizophrenia, was encapsulated in bio-based non-isocyanate polyurethane (NIPU) nanoemulsions. NIPU was synthesized via an isocyanate-free polyaddition route, addressing safety and environmental concerns associated with conventional polyurethanes. The drug-loaded nanoparticles were produced utilizing oil-in-water (O/W) emulsions followed by solvent evaporation and lyophilization. NIPU concentrations of 0.3% and 0.5% w/v, as well as 0.5% w/v PVA were employed, while PP was incorporated at 0.2%, 0.5% and 1% w/v. The formulations were characterized by FTIR, DSC and XRD analyses, and the mechanical strength of neat sponges was evaluated. The nanoparticle formation and size were assessed by DLS and SEM analyses. The water contact angle, porosity measurements and aquatic and enzymatic hydrolysis were additionally performed. The resulting nanocarriers exhibited controlled particle size, increased drug-loading values, structural stability and biodegradability. Lastly, the in vitro dissolution studies revealed a system-specific burst release behavior, and a controlled and sustained overall drug-release profile for majority of the formulations, thereby indicating the potential of NIPU nanocarriers for drug delivery applications, particularly where sustained therapeutic effects are required. Full article

Sustainable nanotechnologies derived from renewable resources are increasingly being positioned at the interface of green chemistry, advanced drug delivery, and translational pharmaceutics. Over the past decade, lignocellulosic nanomaterials, chitin/chitosan platforms, polysaccharide-based nanogels and nano-enabled hydrogels, lignin- and polyphenol-derived nanostructures, and bio-based lipid nanocarriers have been engineered through progressively eco-efficient routes, including solvent-minimized self-assembly, nanoprecipitation, spray drying, hot-melt extrusion, and microfluidic-assisted fabrication. This work provides a structured evidence map of nano-enabled drug delivery and therapeutic platforms derived from renewable biological resources. Specifically, we aim to (i) identify and classify nanoplatform classes and renewable feedstocks; (ii) summarize reported pharmaceutical critical quality attributes (CQAs) and performance and safety endpoints; and (iii) appraise how “renewability” and “green” claims are evidenced (feedstock origin vs. process sustainability) and how frequently translational readiness factors (scalability, quality control, regulatory alignment) are addressed. We critically compare renewable and conventional nanomaterial platforms across key translational dimensions, including carbon footprint, batch consistency, biodegradability, functional tunability, safety/persistence, and scale-up maturity. Finally, we delineate a practical translational pathway—from biomass sourcing and fractionation to nanoformulation, characterization/stability, and GMP scale-up—highlighting cross-cutting enablers such as lifecycle assessment, EHS/toxicology risk assessment, quality-by-design, and regulatory alignment. Collectively, the evidence supports renewable nanomaterials as viable, scalable candidates for next-generation therapeutics, provided that variability control, standardized characterization, and safety-by-design principles are embedded early in development. Full article

Precise drug delivery remains a critical challenge in nanomedicine, with conventional nanocarriers suffering from significant drug leakage during circulation, limited control over release kinetics, and a lack of temporal control. This study presents a computational design and multiphysics simulation of a Smart Biodegradable Nanosystem. Through COMSOL Multiphysics simulations encompassing heat transfer, mass diffusion, and fluid dynamics, we validated the theoretical feasibility of a seven-layer architecture. The computational model predicts that mapping a re-entrant auxetic metamaterial topology onto a spherical scaffold enables geometric locking under fluidic stress, theoretically minimizing drug leakage. Furthermore, modeled thermosensitive dynamic covalent bonds demonstrate highly controlled release kinetics. All performance metrics presented herein are derived from predictive mathematical modeling. Theoretical degradation profiles indicate complete breakdown within 90–180 days into endogenous substances. This simulation-based study establishes a rigorous theoretical blueprint to guide future empirical fabrication in precision nanomedicine. Full article

Protein-based nanocarriers have gained considerable attention for targeted cancer theranostic applications due to their inherent biocompatibility, biodegradability, and facile functionalisation. In addition, some of their properties, such as self-assembling nature, low immunogenicity (if species matched), molecular recognition ability, and lack of persistence due to degradation into proteinogenic amino acids, make them highly suitable for oncology-related applications. Each protein-based nanocarrier exhibits unique physicochemical and biological properties. In this review, we summarise recent advances in targeted protein-based nanocarriers, including albumin, lipoproteins, ferritin, viral protein capsids, fibrin type proteins and silk proteins, emphasising receptor-specific targeting mechanisms, the integration of various imaging modalities along with their advantages and limitations, and the importance of employing advanced preclinical models for translational theranostic applications. This review also discusses the most recent and significant studies in the field, providing useful insights into future directions of protein-based nanocarriers for cancer theranostics. Full article

Two decades after the first bold proclamations that nanomedicine would deliver “magic-bullet” therapies capable of cell-level targeting, the field stands at a crossroads. While some initial promises (improved delivery of poorly water-soluble drugs and enhanced efficacy and biocompatibility of nano-based devices) have been fulfilled, other early promises (active targeting, biodegradability, multifunctionality, triggered responses, real-time data output, and implantable sensors) remain only partially realized. This article will compare the properties of approved nano-based products to those of the ideal products, assess the shortcomings of existing nano-based products, and discuss critical issues in nanotoxicity (biodistribution and protein corona effects, immune interactions, and biopersistence) and the lack of data on product and end-of-life life cycle analyses. The role of in silico tools in the various steps of nanodrug and nano-based device development and manufacturing—areas in which these tools are the most established (nanocarrier design, prediction of cellular effects, chemical composition optimization, manufacturing, and signal interpretation)—is also addressed. Future goals include biodegradable targeted delivery systems, better tissue integration of implants, and implantable sensors. It is expected that, alongside careful physicochemical characterization of the nanoproduct, toxicity testing focused on nano-specific effects and life cycle analyses of production and end-of-life phases will facilitate the approval of nano-based products. Full article

Poly(ethylene glycol) (PEG) has long stood as the prevailing standard in drug delivery, celebrated for its capacity to enhance solubility, extend circulation, and improve pharmacological performance. Nevertheless, the emergence of anti-PEG antibodies, accelerated clearance, and limited biodegradability increasingly undermine its role as a universal solution. In response, a new generation of polymers has been developed to address these shortcomings, offering the potential to sustain or surpass PEG’s benefits while mitigating immunogenicity, improving biocompatibility, and enabling finer control over therapeutic fate. This review examines current research to articulate a coherent perspective on the replacement of PEG, tracing how advances in polymer design are reshaping the foundations of targeted drug delivery. Taken together, these developments signal not only a corrective to the limitations of PEG but also a broader paradigm shift toward safer, more versatile, and clinically translatable systems that define the next frontier in precision therapeutics. Full article

Chronic diseases such as cancer, cardiovascular disorders, neurodegenerative conditions, chronic respiratory diseases, autoimmune disorders, chronic kidney disease, persistent infectious diseases, diabetes, and ocular inflammation remain leading causes of morbidity and mortality worldwide. Their complex pathophysiologies and the limitations of conventional therapies underscore the urgent need for advanced drug delivery platforms that enhance therapeutic efficacy while minimizing off-target effects and systemic toxicity leading to adverse reactions. Nanomedicine has emerged as a transformative approach, with chitosan-based nanocarriers offering advantages due to their biocompatibility, biodegradability, mucoadhesive properties, and ability to be physic-chemically modified. These nanocarriers improve solubility, stability, bioavailability, and the therapeutic index of drugs, while enabling controlled release, targeted delivery, and immune modulation. This review highlights recent advances in chitosan-based nanomedicine for the management of chronic disease. We discuss methods of synthesis such as ionic gelation and electrospray, functionalization approaches, and immunomodulatory roles that expand therapeutic potential. The evidence emphasizes that chitosan nanocarriers are a versatile, safe, and effective platform which can be used to improve clinical results, reduce adverse effects, and advance the science of personalized medicine. Full article

The shift toward sustainable packaging requires biodegradable, active alternatives. This study developed ternary nanohybrids by loading carvacrol (CV) or trans-cinnamaldehyde (tCN) onto zinc oxide/natural zeolite (ZnO/NZ) hybrids, which were incorporated into a poly-L-lactide/tri-ethyl citrate (PLA/TEC) matrix via melt extrusion to produce active films. A key finding was the distinct interaction mechanism: tCN underwent strong chemisorption with ZnO, creating a sustained-release reservoir, while CV was predominantly physisorbed, leading to rapid release. This interfacial divergence dictated functional performance. Antibacterial assessment of nanohybrids revealed that tCN@ZnO/NZ0.25 exhibited the highest inhibition zones against pathogens, correlating with its chemisorbed reservoir. In films, however, CV-based formulations (especially CV@ZnO/NZ0.25) showed superior immediate antioxidant activity (EC₅₀, ~DPPH~ = 34.43 mg/mL) and an 82% reduction in oxygen permeability. In contrast, tCN-based films (especially tCN@ZnO/NZ1.0) demonstrated superior, sustained antibacterial efficacy. In a minced pork preservation study, both films delayed lipid oxidation and preserved heme iron, while the tCN-based film provided better long-term microbial control. This work demonstrates that engineering the nanocarrier–active compound interface enables precise tailoring of release kinetics, which can be optimized for either high immediate antioxidant power or long-term antimicrobial action, depending on specific food preservation requirements. Full article

Poly (lactic-co-glycolic acid) (PLGA) is a widely used copolymer with applications across medical, pharmaceutical, and other industrial fields. Its biodegradability and biocompatibility make it one of the most versatile polymers for nanoscale drug delivery. The present review addresses current knowledge and recent advances in PLGA-based co-delivery nanoformulations with a special reference to design strategies, functional mechanisms, and translational potential. Conventional and advanced fabrication methods, the structural design of PLGA-based nanocarriers, approaches to scale-up and reproducibility, classification of co-delivery types, mechanisms governing drug release, surface modification and functionalization are all discussed. Special attention is given to PLGA-based co-delivery systems, encompassing drug–drug, drug–gene, gene–gene and multi-modal combinations, supported by recent studies demonstrating synergistic therapeutic outcomes. The review also examines clinical translation efforts and the regulatory landscape for PLGA-based nanocarriers. Unlike most existing reviews that typically focus either on PLGA fundamentals or on co-delivery approaches in isolation, this article bridges these domains by providing an integrated, comparative analysis of PLGA-based co-delivery systems and elucidating a critical gap in linking design strategies with translational requirements. In addition, by emphasising the relevance of PLGA-based co-delivery for combination therapies, particularly in cancer and other complex diseases, the review highlights the strong clinical and translational potential of these platforms. Key challenges, such as reproducibility, large-scale manufacturing, and complex regulatory pathways, are discussed alongside emerging trends and future perspectives. Taken together, this review positions PLGA-based co-delivery strategies as a critical driver for advancing precision therapeutics and shaping the future landscape of nanomedicine. Full article

Liposomes started to be studied for drug delivery in 1970s, taking advantage of their ability to encapsulate hydrophilic and hydrophobic drugs using biodegradable and biocompatible molecules. Nowadays, they remain one of the most promising strategies for drug delivery not only in cancer treatment but also in gene therapies and vaccines. The design and development of liposomal systems have evolved significantly over the past decades, moving from conventional formulations to advanced, stimulus-responsive, and multifunctional nanocarriers. Analogous to the myth of the Trojan Horse, liposomes must mislead the host immune system to reach the interior of cancer cells in order to deliver the therapeutic payload. There are many barriers that liposomes have to overcome to circulate through the bloodstream and specifically target cancer cells without damaging other tissues. Crucial parameters such as lipid composition, particle size, zeta potential, and PEGylation have been systematically optimized to enhance pharmacokinetics and biodistribution and to improve delivery efficiency. Furthermore, conjugation with antibodies, peptides, or small molecules has enabled active targeting, while stimuli such as pH, temperature, and enzymatic activity have been exploited for controlled drug release within the tumor microenvironment. Such innovations have laid the groundwork for translating liposomal formulations from the bench to clinical applications. In this paper, we evaluate the physicochemical features of liposomal design that underpin their suitability and efficacy for anticancer drug delivery. We aimed to focus on two main aspects: conducting an exhaustive review of the physicochemical parameters of liposomal drugs that have already been approved by regulatory agencies, while maintaining a pedagogical approach when explaining the key design parameters for the optimal design of liposomes in oncology in detail. Full article

Exogenous insulin is essential for diabetes management; however, subcutaneous administration is associated with discomfort, poor adherence and non-physiological peripheral hyperinsulinemia. Oral administration would better mimic the physiological insulin distribution route but is hampered by gastrointestinal barriers, resulting in low bioavailability. Enabling access to the market for oral insulin nanocarriers requires rigorous control of their physicochemical attributes (size, charge, and surface chemistry) to ensure biocompatibility and mitigate risks such as the long-term bioaccumulation of non-biodegradable materials and the loss of intended targeting due to protein corona formation. In pre-clinical studies, nanoparticle carriers have shown promising results by protecting insulin and enhancing its absorption, yet clinical translation remains limited, with most candidates stalling in early-phase trials. This translational gap stems from the inadequacy of conventional animal models and regulatory frameworks to address the complexity of nanomedicines. This review goes beyond a simple summary of nanocarrier types and discusses the non-clinical and regulatory challenges hampering progress. We highlight the limitations of current preclinical models and the challenge of evaluating the pharmacokinetic profiles of both the nanocarrier and its insulin payload. The development of more rigorous and predictive strategies based on most recent successes and failures, described in this review, could help to bridge the translational gap. Full article

Polymeric micelles are widely studied as nanocarriers for hydrophobic drugs, yet their structural stability under physiological conditions remains a major limitation. This review provides a comparative evaluation of synthetic and natural polymeric micelles with a focus on their stability under dilution and in protein-rich environments. The discussion integrates thermodynamic and kinetic factors governing micelle integrity and examines how molecular composition, hydrophobic segment length, and core–shell modifications influence disintegration behavior. While synthetic micelles commonly collapse below their critical micelle concentration during intravenous administration, natural polymeric micelles, such as those derived from chitosan, alginate, or heparin, exhibit improved resistance to dilution but remain vulnerable to protein-induced destabilization. Strategies such as core or shell cross-linking, surface functionalization, and natural polymer coatings are reviewed as promising approaches to enhance circulation stability and controlled drug release. The work provides a framework for designing micellar systems with balanced biocompatibility, biodegradability, and robustness suitable for clinical drug-delivery applications. Full article